Abstract 554P
Background
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a useful diagnostic modality for thoracic lymphadenopathies, including primary lung cancer. However, the specimens obtained are often small and inadequate for pathological diagnosis. We previously reported that using the EchoTip ProCore Endobronchial HD ultrasound needle (EchoTip) increased the tissue diagnosis rate in lung cancer (Miyazaki et al., 2021). In previous studies, the Oncomine Dx Target Test (ODxTT) was performed in only one case, and it is unclear whether the specimens collected could tolerate next-generation sequencing (NGS)-based testing.
Methods
We performed a single-center, retrospective observational study. This study included patients who underwent ODxTT between April 1, 2019 and April 30, 2023. Patients were selected and divided into two groups comprising those who underwent EBUS-TBNA and those whose specimens were obtained by other methods. The ODxTT success rate was calculated for each group. This study was approved by the institutional review board in June 2022. (No. 22-06-05).
Results
We enrolled 144 patients:20 in the EBUS-TBNA group and 124 in the other-methods group. In the EBUS-TBNA group, the pathological diagnoses were adenocarcinoma (Ad), squamous cell carcinoma (Sq), and others in 15, 2, and 3 patients, respectively. In contrast, in the other-methods group, the collection methods were endobronchial biopsy and transbronchial biopsy, surgical procedures, computed tomography-guided needle biopsy, and others for 79, 31, 6, and 8 patients, respectively, and the pathological diagnoses were Ad, Sq, and others in 78, 15, and 31 patients, respectively. The success rates of ODxTT for EBUS-TBNA and others were 90% and 86%, respectively. The DNA and RNA inspection success rates of EBUS-TBNA were 95% and 90%, respectively, and those of the other methods were 90% and 94%, respectively.
Conclusions
The success rate of ODxTT on EBUS-TBNA specimens were 90%. It is expected to yield specimens of sufficient quality and quantity to perform ODxTT and may be an important diagnostic option in lung cancer cases with enlarged lymph nodes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
K. Miyazaki: Financial Interests, Personal, Invited Speaker: AstraZeneca, Merck KGaA, Eli Lilly Japan K.K., Cook Medical Japan; Financial Interests, Institutional, Research Grant: AbbVie GK, MSD, AstraZeneca, Bristol Myers Squibb, Taiho Pharmaceutical CO., LTD. K. Ito, A. Hayashi: Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical CO., LTD., MSD, AstraZeneca, Bristol Myers Squibb, AbbVie GK. A. Shiba: Financial Interests, Institutional, Research Grant: AstraZeneca, MSD, Taiho Pharmaceutical CO., LTD., Bristol Myers Squibb, AbbVie GK. Y. Higashi: Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical CO., LTD., MSD, AstraZeneca, Bristol Myers Squibb, AbbVie GK. M. Aga: Financial Interests, Personal, Invited Speaker: TEIJIN PHARMA, Nippon Boehringer Ingelheim Co., Ltd.; Financial Interests, Institutional, Research Grant: AbbVie GK, Bristol Myers Squibb, Taiho Pharmaceutical CO., LTD., MSD, AstraZeneca. Y. Hamakawa: Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical CO., LTD., Chugai Pharmaceutical CO., LTD, Ono Pharmaceutical CO., LTD., AstraZeneca, AbbVie GK. Y. Taniguchi: Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical CO., LTD., MSD, Bristol Myers Squibb, AstraZeneca, AbbVie GK; Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharmaceutical CO., LTD, Ono Pharmaceutical CO., LTD. Y. Misumi: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharmaceutical CO., LTD, Ono Pharmaceutical CO., LTD., Nippon Kayaku CO., LTD., Taiho Pharmaceutical CO., LTD.; Financial Interests, Institutional, Research Grant: MSD, AstraZeneca, Bristol Myers Squibb, AbbVie GK, Taiho Pharmaceutical CO., LTD. Y. Agemi: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharmaceutical CO., LTD, Ono Pharmaceutical CO., LTD., Bristol Myers Squibb, Takeda Pharmaceutical Company Limited, Kyowa Hakko Kirin Co., Ltd.; Financial Interests, Institutional, Research Grant: AstraZeneca, Bristol Myers Squibb, AbbVie GK, Taiho Pharmaceutical CO., LTD., MSD. Y. Nakamura: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharmaceutical CO., LTD, Taiho Pharmaceutical CO., LTD.; Financial Interests, Institutional, Research Grant: AstraZeneca, Taiho Pharmaceutical CO., LTD., MSD, Bristol Myers Squibb, AbbVie GK. T. Shimokawa: Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical CO., LTD., MSD, Bristol Myers Squibb, AstraZeneca, AbbVie GK. H. Okamoto: Financial Interests, Institutional, Research Grant: MSD, Taiho, Bristol Myers Squibb.
Resources from the same session
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract